Literature DB >> 21811210

Transscleral albumin diffusion and suprachoroidal albumin concentration in uveal effusion syndrome.

Timothy L Jackson1, Ali Hussain, Jon Salisbury, Roy Sherwood, Paul M Sullivan, John Marshall.   

Abstract

PURPOSE: To test the hypothesis that uveal effusion syndrome is caused by reduced transscleral albumin permeability.
METHODS: Surgical scleral specimens were obtained from a 55-year-old patient with nanophthalmic uveal effusion syndrome. Specimens were clamped in a modified Ussing chamber, and the rate of transscleral diffusion of fluorescein isothiocyanate-albumin was measured over 12 hours, using a spectrophotometer and predetermined standard curves. The diffusion coefficient was determined at 20°C, and then adjusted to body temperature using Einstein's equation. Results in 3 scleral samples were compared with 10 age-matched controls. Albumin and total protein concentration were measured in choroidal fluid and serum.
RESULTS: Histologic staining with Alcian blue showed interfibrillary acid mucin deposits. Transmission electron microscopy showed deposits measuring 1 μm to 10 μm and collections of expanded, degenerate collagen fibrils. The mean (±SD) albumin diffusion coefficient was 12% of that in controls (1.22 ± 0.67(-8) × 10 vs. 10.3 ± 7.0 × 10(-8) cm2/second) and below the lower 95% confidence limit of the control group. The diffusion coefficient was calculated to increase 53% to 1.87 ± 1.03 × 10(-8) cm2/second at 37°C. Choroidal albumin concentration was much higher than physiologic levels, measuring 200 g/L (total protein 321 g/L), 5 times the serum albumin concentration of 42 g/L (total protein 70 g/L).
CONCLUSION: Nanophthalmic uveal effusion syndrome can be associated with reduced scleral permeability to albumin, and a very high concentration of retained suprachoroidal albumin. This will lead to an osmotic gradient that retains fluid and may partly explain the pathogenesis of uveal effusion syndrome in some patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21811210     DOI: 10.1097/IAE.0b013e318218a95a

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Medical therapy for uveal effusion syndrome.

Authors:  B Andrijević Derk; G Benčić; V Corluka; M Zorić Geber; Z Vatavuk
Journal:  Eye (Lond)       Date:  2014-06-06       Impact factor: 3.775

2.  Suprachoroidal injection of ketorolac tromethamine does not cause retinal damage.

Authors:  Sumeng Liu; Wu Liu; Yaling Ma; Kegao Liu; Meizi Wang
Journal:  Neural Regen Res       Date:  2012-12-15       Impact factor: 5.135

3.  Isolated posterior uveal effusion: expanding the spectrum of the uveal effusion syndrome.

Authors:  Scott E Pautler; David J Browning
Journal:  Clin Ophthalmol       Date:  2014-12-30

4.  Uveal effusion syndrome in 104 eyes: Response to corticosteroids - The 2017 Axel C. Hansen lecture.

Authors:  Carol L Shields; Kelsey Roelofs; Maura Di Nicola; Kareem Sioufi; Arman Mashayekhi; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2017-11       Impact factor: 1.848

5.  Drainage and analysis of suprachoroidal fluid in a patient with acute systemic lupus erythematous.

Authors:  James A Stefater; Dean Eliott; Leo A Kim
Journal:  Am J Ophthalmol Case Rep       Date:  2016-11-14

6.  Comparing the Results of Vitrectomy and Sclerectomy in a Patient with Nanophthalmic Uveal Effusion Syndrome.

Authors:  Ivajlo Popov; Veronika Popova; Vladimir Krasnik
Journal:  Medicina (Kaunas)       Date:  2021-01-29       Impact factor: 2.430

7.  Cataract Surgery in Short Eyes, Including Nanophthalmos: Visual Outcomes, Complications and Refractive Results.

Authors:  Jason C Yosar; Sophia L Zagora; John R Grigg
Journal:  Clin Ophthalmol       Date:  2021-11-27

8.  Diagnosis and a minimum effective management for nanophthalmic uveal effusion syndrome.

Authors:  Wei Jin; Yaopeng Xu; Wenjun Wang; Anhuai Yang
Journal:  Indian J Ophthalmol       Date:  2016-08       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.